---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091175"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:19:49.652998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q2 net loss $52.8M; darovasertib neoadjuvant UM shows tumor shrinkage; IDE397 39% ORR in MTAP-deletion tumors

## Summary
- Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.
- Cash $952.7M at June 30; July public offering netted $283.8M, extending runway into at least 2028.
- Darovasertib in neoadjuvant UM: Phase 2 enrolled >50 patients; median tumor shrinkage ~72% volume; FDA Type C meeting in Q3.
- IDE397 in MTAP-deletion tumors: 39% ORR (1 CR, 6 PR), 94% DCR in 18 evaluable patients; selected 30 mg expansion dose.
- Entered option/license agreement with Biocytogen for B7H3/PTK7 BsADC; DC nomination targeted H2 2024; potential milestones $406.5M.

## SEC filing metadata
- accession: 0000950170-24-091175
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/0000950170-24-091175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/idya-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091175
- JSON: https://secwatch.observer/filing/0000950170-24-091175.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.